Agenda
DAY 1
DAY 2
Session I
HR+
Friday, September 18, 2026
8:05 am
—
9:25 am
Credits Available
View Full Attendance Credit
Session Moderator(s)
PRESENTATIONS IN THIS SESSION
Optimizing Endocrine and Targeted Therapy for Early Stage HR+/HER2- Breast Cancer
Decoding Gene Expression Assays for Early-Stage HR+/HER2- Therapy Planning
Evolving Insights Related to Minimal Residual Disease Monitoring in Breast Cancer
Audience Q&A and Panel Discussion